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Abstract 
Ethnopharmacological relevance: Leaves from the plant species studied herein are traditionally 
used in northern Nigeria against various protozoan infections. However, none of these herbal 
preparations have been standardized, nor have their toxicity to mammalian cells been 
investigated. In search of improved and non-toxic active antiprotozoal principles that are not 
cross-resistant with current anti-parasitics, we here report the results of the in vitro screening of 
extracts from seven selected medicinal plant species (Centrosema pubescens, Moringa oleifera, 
Tridax procumbens, Polyalthia longifolia, Newbouldia laevis, Eucalyptus maculate, Jathropha 
tanjorensis), used traditionally to treat kinetoplastid infections in Nigeria, and the isolation of 
their bioactive principles. 
Aim of the study: To investigate the efficacies of medicinal plant extracts, and of compounds 
isolated therefrom, against kinetoplastid parasites, assess cross-resistance to existing 
chemotherapy, and assay their toxicity against mammalian cells in vitro. 
Material and methods: Plants were extracted with hexane, ethyl acetate and methanol. Active 
principles were isolated by bioassay-led fractionation, testing for trypanocidal activity, and 
identified using NMR and mass spectrometry. EC50 values for their activity against wild-type 
and multi-drug resistant Trypanosoma brucei were obtained using the viability indicator dye 
resazurin.  
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Results: Seven medicinal plants were evaluated for activity against selected kinetoplastid 
parasites. The result shows that crude extracts and isolated active compounds from Polyalthia 
longifolia and Eucalyptus maculata, in particular, display promising activity against drug-
sensitive and multi-drug resistant Trypanosoma brucei. The EC50 value of a clerodane (16α-
hydroxy-cleroda-3,13(14)-Z-dien-15,16-olide) isolated from Polyalthia longifolia was as low as 
0.38 µg/mL, while a triterpenoid (3β,13β-dihydroxy-urs-11-en-28-oic acid) isolated from 
Eucalyptus maculata displayed an EC50 of 1.58 µg/mL. None of the isolated compounds 
displayed toxicity towards Human Embryonic Kidney cells at concentrations up to 400 µg/mL. 
In addition, the isolated compounds were active against Leishmania mexicana, as well as 
against T. congolense.  
Conclusion: We have isolated a clerodane compound from Polyalthia longifolia that shows low 
toxicity, no cross-resistance with current treatments, and promising activity against both human-
infective and veterinary Trypanosoma species. 
 
Keywords: Antiparasite chemotherapy, ethnopharmacology, extracts, Leishmania mexicana, 
purified compounds, Trypanosoma brucei. 
 
*Correspondence to: Institute of Infection, Immunity and Inflammation, College of Medical, 
Veterinary and Life Sciences, Sir Graeme Davies Building, University of Glasgow, 120 
University Place, Glasgow G12 8TA. 
 
E-mail address: Harry.De-Koning@glasgow.ac.uk 
  
1. Introduction 
Infectious diseases that are caused by certain species of the genera Trypanosoma (Human 
African trypanosomiasis or HAT, and Chagas disease) and Leishmania (various forms of 
leishmaniasis) are amongst the neglected tropical disease, affecting many millions of people 
throughout the tropics. Mortality and morbidity resulting from these diseases is still very high in 
developing countries (Hotez and Kamath, 2009; Hotez et al., 2009). New and improved 
treatments would undoubtedly enhance the welfare of the local population and livestock 
(Nwodo et al., 2015; Giordani et al., 2016). While mortality due to HAT is clearly important, 
African Animal Trypanosomiasis (AAT or nagana) is considered the livestock disease with the 
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highest impact on agricultural production and animal husbandry in Africa, causing annual losses 
which run to billions of US dollars (Samdi et al., 2010). Across the tsetse belt as many as 55 
million heads of cattle are at risk of infection, plus 30 million sheep and 40 million goats. It is 
estimated that 3 million cattle die every year from African trypanosomiasis (Samdi et al., 2010; 
Seyoum et al., 2013).  
 
African trypanosomiasis and leishmaniasis as global health challenges are compounded by the 
lack of vaccines, making chemotherapy the only suitable alternative at the moment (La Greca 
and Magez, 2011). In addition, existing antiparasitic drugs are hampered by toxic side effects 
and the emergence of resistance (Delespaux and De Koning, 2007; Fairlamb et al., 2016). 
However, natural products have been identified as highly promising starting points for the 
discovery of anti-protozoan agents (e.g. Salem and Werbovetz, 2006; Omar et al., 2016; Siheri 
et al., 2016; Dike et al., 2016), and indeed have a long and distinguished history as essential 
drugs in the fight against tropical disease (e. g. Tu  2011). Indeed, over the period 1981-2002, 
61% of all new chemical entities approved for infectious diseases were natural compounds or 
directly derived thereof (Newman et al., 2003).  
 
Natural products derived from plants have played an important role in the control of diseases 
caused by the protozoal parasites, a classical example is malaria caused by Plasmodium 
falciparum. Current malaria treatment relies heavily on plant-derived products, including the 
sesquiterpene lactone artemisinin (Wells, 2011), and the alkaloid quinine (Moyo et al., 2016). 
The success stories of artemisinin, isolated from the Chinese wormwood plant (Artemisia 
annua) and of quinine, isolated from the bark of cinchona trees (Cinchona officinalis), both 
used traditionally as antimalarial therapies, justify drug discovery based on 
ethnopharmacological usage, as these drugs were discovered following an intensive screening of 
hundreds of plants traditionally used for treating malaria (Tu, 2011).These achievements 
notwithstanding, unfortunately, fewer efforts have been put into investigating extracts from 
various plants traditionally used for treating the kinetoplastid diseases like trypanosomiasis and 
leishmaniasis despite the undesirable side effects and marginal effectiveness of the currently 
available drugs.  
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Centrosema pubescens, Moringa oleifera, Tridax procumbens, Polyalthia longifolia, 
Newbouldia laevis, and Eucalyptus maculata thrive well in many areas of Nigeria where they 
grow in the wild except for Moringa oleifera, which is cultivated for food and for medicinal 
use. Newbouldia laevis is mostly used in northern Nigeria for boundary demarcation, while 
Polyalthia longifolia commonly called ‘‘mast tree’’ is used as an ornamental plant. These plants 
are highly valued and are also used for treating various infections caused by the protozoan 
parasites including species of Trypanosoma, Leishmania, and Plasmodium, especially the 
strains that resists existing chemotypes (Tor-Anyiin et al., 2003; Igoli et al., 2004, 2005; Alli et 
al., 2011; Abubakar et al., 2012; Nwodo et al., 2015; Bankole et al., 2016) . Unfortunately none 
of the herbal preparations from these plants have been standardized for use, nor extensively 
investigated for their toxicity on mammalian cells, and their activity against protozoan parasites 
has not been scientifically validated. Because these plants grow on many soil types, are 
abundant in the wild, and only their leaves are used, their utilization as herbal remedies pose no 
danger to biodiversity. 
 
The development of an effective chemotherapy based on a local resource will ensure new drugs 
that will both address the urgent need for new treatments and provide an additional economic 
driver for poor farming communities. In this study, we investigate the anti-kinetoplastid 
potential of selected herbs traditionally used for treating infections caused by trypanosomatid 
parasites in northern Nigeria. 
 
2. Materials and Methods 
2.1. Plant selection and collection  
In Nigeria, the use of traditional herbal medicine is part of the unique tradition acceptable to the 
majority of the people (Sofowora, 1993; Heinrich, 2000; Adetutu et al., 2011). This 
notwithstanding, the secrecy associated with this practice has led to a paucity of scientific 
reporting of this knowledge in literature (Ashidi et al., 2010). However, the selection of 
traditional medicinal plants used in the present study is based on interviews with traditional 
healers who were willing to divulge the information. Following the method of Adetutu et al. 
(2011), ethnopharmacological methods were used to select the plants used in this research.  
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Briefly, the selection followed interviews with the traditional healers, using structured 
questionnaires to establish which plant and part of the plant is in common use against tropical 
fevers. Thirty-one traditional healers were approached, with eighteen volunteering to complete 
the survey. The information collected included local names of the plants used for treating 
various forms of fevers, parts of the plant commonly used, methods of preparation, and details 
of administration. The frequency of citation of each plant was recorded. Seven plants were 
consistently cited. The selected plants were purchased from the healers and their specimens 
were used for identification at the herbarium of Kogi State University, Nigeria.  Each plant 
name has been checked with www.theplantlist.org and this website was last accessed on the 
06/01/2017. The plants were identified as shown in Table 1: 
 
Table 1. Botanical name and voucher number for each plant evaluated in this study. 
Code Botanical name Voucher number 
A Centrosema pubescens Benth. (Family Fabaceae) 0446 
B Moringa oleifera Lam (Family Moringaceae) 0447 
C Tridax procumbens (L.) L. (Family Compositae) 0448 
D Polyalthia longifolia (Sonn.) Thwaites (Family Annonaceae) 0449 
E Newbouldia laevis (P.Beauv.) Seem. (Family Bignoniaceae) 0450 
F Eucalyptus maculata Hook. (Family Myrtaceae) 0451 
G Jatropha tanjorensis J.L.Ellis & Saroja (Family Euphorbiaceae) 0452 
 
Plant collection was carried out in the months of January and February 2014 from the town of 
Anyigba, Kogi State, Nigeria (latitude 7º 15’ - 7º 29’ N and longitude 7º 11’- 7º 32’ E; altitude 
of 410 – 430 m). 
 
2.2. Extraction procedure 
The leaves of the plants were thoroughly air dried and subsequently were ground to a fine power 
using a grinder before extraction. 
The powdered dry leaves (20 g) were weighed into an extraction thimble (Fisher Scientific) and 
placed in a Soxhlet apparatus. The plant materials were extracted consecutively using solvents 
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of increasing polarity starting with n-hexane and followed by ethyl acetate and methanol (500 
mL of each solvent; all obtained from Fisher Scientific (Loughborough, UK)). Each extraction 
stage was carried out to exhaustion. All extracts obtained were evaporated at 40 ºC; recovery of 
solvent, and concentration of the extracts, was carried out under vacuum using a rotary 
evaporator connected to a condenser. Residual solvents were further allowed to evaporate under 
the fume hood before samples were freeze dried in a freeze dryer. The hexane, ethyl acetate, and 
methanol extracts obtained were labelled as below, then stored at -20 ºC prior to analysis.  The 
yields of the crude extracts were between 2-5 g. 
Samples were labelled accordingly as: 
HDK-AE; HDK-AH; HDK-AM – Ethyl acetate, Hexane, and Methanolic fractions from plant A 
respectively.  
HDK-BE; HDK-BH; HDK-BM – Ethyl acetate, Hexane, and Methanol fractions from plant B 
respectively. 
HDK-CE; HDK-CH; HDK-CM – Ethyl acetate, Hexane, and Methanol fractions from plant C 
respectively. 
HDK-DE; HDK-DH; HDK-DM – Ethyl acetate, Hexane, and Methanol fractions from plant D 
respectively. 
HDK-EE; HDK-EH; HDK-EM – Ethyl acetate, Hexane, and Methanol fractions from plant E 
respectively. 
HDK-FE; HDK-FH; HDK-FM – Ethyl acetate, Hexane, and Methanol fractions from plant F 
respectively. 
HDK-GE; HDK-GH; HDK-GM – Ethyl acetate, Hexane, and Methanol fractions from plant G 
respectively. 
 
Bioactivity-guided fractionation was carried out according to the method described by Ene et al 
2009, which involves testing the activity of each fraction at each stage of fractionation with the 
aim of further purifying each active fraction until a pure compound is obtained. As detailed 
below the fractionation utilizes various chromatographic techniques and purity is assessed using 
nmr. The yields of the pure compounds were between 10-15 mg with % purity of 80-95 % (See 
Table 2). 
 
Table 2. Yield and Percentage purity of purified compounds. 
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Compounds 
weight  of purified 
compound (mg) 
Weight of dry material 
(leaves) (kg) Yield (mg/kg) % purity 
HDK20 15.21 20 0.7605 94.05 
HDK40 13.75 20 0.6875 95.21 
HDK52 14.22 20 0.711 94.04 
HDK79 10.03 20 0.5015 80.91 
 
2.3 Size exclusion chromatography 
For non-polar fractions, Sephadex® LH-20 (GE Healthcare Life Sciences) was soaked in a 
solution of 5% n-hexane in dichloromethane or 50% dichloromethane (Sigma-Aldrich) in 
methanol for several hours. The slurry was then poured and packed in a glass chromatography 
column of appropriated size containing about 10-15 mL of solvent allowed to freely drip in 
order to prevent air bubbles. Samples were dissolved in a small volume of the solvent used for 
the mobile phase. The concentrated sample was loaded at the top of the column. Elution was 
with 5% n-hexane in dichloromethane or 50% dichloromethane in methanol. If needed, elution 
was continued with 100% dichloromethane or 100% methanol, respectively. For relatively polar 
fractions, Sephadex® was soaked in methanol and the column was then eluted with the same 
solvent. When column finished, Sephadex® was washed with water then methanol and kept 
dried for re-use.  
 
2.4 Silica gel chromatography 
Open Column Chromatography was performed on silica gel 60 (mesh size 0.063-0.200 mm 
(Sigma-Aldrich)). The column was packed using the wet packing technique. Silica gel 60 was 
made into slurry using the least polar solvent of the eluting system and then poured and packed 
in a glass chromatography column of appropriate size. Air bubbles were eliminated by tapping 
the side of the column, and by allowing the tap to run while packing; excess solvent was 
allowed to run through and the column was left to settle. Samples were dissolved in a suitable 
solvent and adsorbed on a small amount of silica gel 60 (mesh size 0.063-0.200 mm), which 
was loaded onto the column. Elution was carried out either isocratically or using a gradient. The 
collected fractions were analyzed by thin layer chromatography (see supplementary figure S1 for 
details) and pooled according to similar chemical profiles. 
 
2.5 Compound Identification 
2.5.1 NMR spectroscopy 
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1H and 13C- and 2D NMR experiments were carried out on a JEOL (JNM LA400) 400 MHz and 
on a Bruker 500 or 400 MHz instrument. NMR tubes (5 mm) purchased from Wilmad-labglass 
were used for routine NMR experiments. Samples were dissolved in about 0.6 mL of NMR 
grade deuterated chloroform (Sigma-Aldrich) and taken in NMR tubes.  The identification of 
pure compounds was first carried out by one dimensional 1H and 13C-NMR spectroscopy. 
Spectra obtained for known compounds were identified following comparison with published 
spectral data. Further 2D NMR experiments were carried out when necessary to accurately 
assign proton and carbon chemical shifts and, in some cases, to determine relative 
stereochemistry. Note that the NMR spectra of the main compounds identified are given as 
Supplementary Data (Tables S1-S4). 
2.5.2 Mass spectrometry 
High and low resolution electron impact mass spectra were recorded on a JEOL 505HA 
spectrometer using direct probe at elevated temperature (110-160℃) at 70 eV. Positive ion and 
negative ion mode Electrospray Ionisation (ESI) experiments were performed on a 
ThermoFinnigan LCQ-Deca ion trap or Orbitrap HRESI mass spectrometer (mass analyser set 
up at 100,000 ppm, externally calibrated at 3 ppm). According to the polarity, samples were 
dissolved in acetonitrile (Fisher Scientific), methanol or water (HPLC grade, produced in-house 
using a Millipore Milli-Q system) or in a binary mixture of these solvents to get a concentration 
of 100 μg/mL. Sample solution (10-20 μL) was injected along with a direct infusion of 0.1 % 
formic acid in acetonitrile: water (90:10) at a flow rate of 200 μL/min.  
 
2.6. Trypanosoma and Leishmania strains 
To determine the anti-kinetoplastid potential of the selected medicinal plants, the following 
trypanosome strains were used: (1) Wild type strain Trypanosoma brucei Lister 427 (WT); (2) 
A diamidine-resistant strain, TbAT1-KO, which was obtained by knock-out of the TbAT1 
aminopurine transporter (Matovu et al., 2003); (3) A multi-drug resistant strain, B48, which was 
derived from a TbAT1-KO strain after increasing exposure to pentamidine and lacks both the 
TbAT1 transporter and the high affinity pentamidine transporter (HAPT) (Bridges et al., 2007); 
(4) Strain T. brucei R0.8, which is resistant to cAMP phosphodiesterase inhibitors, after 
adaptation to the PDE inhibitor Cpd A (now renamed as NPD-001) (De Koning et al., 2012; 
Gould et al., 2013); (5) Wild type strain Trypanosoma congolense  (6); Wild type Leishmania 
mexicana M379 IL3000 (Al-Salabi and De Koning, 2005). All T. b. brucei strains were used 
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only as bloodstream trypomastigotes, and cultured in standard HMI-9 medium (Life 
Technologies), supplemented with 10 % heat inactivated Fetal Bovine Serum (FBS; Life 
Technologies), 14 µL β-mercaptoethanol, and 3.0 g sodium hydrogen carbonate per litre of 
medium (pH7.4) in vented flasks at 37 ºC in a 5% CO2 atmosphere (Gudin et al., 2006). 
Bloodstream forms of the T. congolense savannah-type strain IL3000 were cultured exactly as 
described by Coustou et al. (Cousteau et al., 2010) and were kindly provided by Theo Baltz 
(Université Victor Segalen Bordeaux 2, Bordeaux, France). Culturing of L. mexicana 
promastigotes was performed in HOMEM with 10% FBS at 25 ºC as described (Al-Salabi et al., 
2003). 
 
2.7 Drug susceptibility assays 
2.7.1 Drug susceptibility assay in trypanosomes 
The drug susceptibilities of bloodstream form trypanosomes were determined using the 
resazurin (Alamar blue) assay (Gould et al., 2008). This involves adjusting the cell density to 
the desired concentration of 2 × 105 cells/mL in HMi-9/FBS. 100 μl of this suspension was 
added to each wells of a 96-well culture plate, pre-prepared with a double dilution of the test 
compounds in 100 µL of the same medium. Typically, the first well contained 400 µg/mL of 
test compound and dilutions would be over 23 wells (i.e. 2 rows of the plate), with the last well 
of row 2 receiving 100 µL of medium as drug-free control. The cells were incubated with the 
test compounds for a period of 48 h at 37 ºC (for T. brucei) or 34 ºC (for T. congolense),  
followed by the addition of 20 µL of a 500 μM resazurin sodium salt (Sigma) solution in PBS 
(pH 7.4), and a further 24 h incubation. Two standard drugs, pentamidine and diminazene 
aceturate (both obtained from Sigma) were used as control at each independent replicate 
determination (n>3). Fluorescence was measured using a FLUOstar Optima (BMG Labtech, 
Durham, NC, USA) at wavelengths of 544 nm for excitation, 590 for emission. EC50 values 
were calculated by non-linear regression using an equation for a sigmoidal dose-response curve 
with variable slope (Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). 
 
2.7.2 Drug susceptibility assay of L. mexicana 
The drug susceptibility assay for promastigotes of L. mexicana was performed the same way as 
for trypanosomes, with minor modifications. Cells were grown in HOMEM medium (pH 7.4) 
with 10% FBS, and the final cell density in each well was adjusted to 1×106 cells/mL. The 
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plates were incubated at 25 ºC + 5% CO2 for 72 hours followed by the addition of 20 μl of the 
500 µM resazurin sodium salt/PBS to every well, and a further incubation period of 48 hours 
prior to reading the fluorescence. 
 
2.8 Cytotoxicity assay using Human Embryonic Kidney (HEK) Cells 293T 
Toxicity of drugs to mammalian cells was tested using Human Embryonic Kidney (HEK) Cells. 
Briefly, HEK Cells were grown in a standard culture containing 500 mL Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma), 50 mL new born Calf Serum (NBCS) (Gibco), 5 mL 
Penicillin/Streptomycin (Gibco) and 5 mL L-Glutamax (200 mM, Gibco). The cells were 
incubated at 37 ºC + 5% CO2 ratio in vented flasks and were passaged when they reached 80-
85% confluence. For the assay, harvested cells were adjusted to a density of 3 × 105 cells/mL 
and 100 µL of this suspension was added to each well of a 96-well plate, each well containing 
3×104 cells. The plate was incubated at 37 ºC + 5% CO2 for 24 hours to allow the cells to adhere 
to the bottom of the plate. Drug stocks were prepared by doubling dilution in DMEM medium 
in a separate 96-well plate; phenyl arsine oxide (PAO (Sigma)) was used as positive control. At 
the end of the 24 hours incubation period, 100 µL/well of the plate that contains the drug 
dilution series was transferred to the opposite well on the plate that contained the HEK cells. 
The plate was then incubated at 37 ºC + 5% CO2 for an additional 30 h followed by the addition 
of 10 µL of sodium resazurin solution and a further incubation at 37 ºC + 5% CO2 for 24 hours 
prior to reading the fluorescence as above. EC50 values were determined from Sigmoid curves 
(Prism 5.0) and for each compound the Selectivity Index (SI) was calculated as EC50(HEK)/ 
EC50(test organism).  
 
3. Results 
 
3.1 Antitrypanocidal activity and cross resistance studies of extracts using wild type 
and multi-drug resistant strains of T. brucei. 
A total of 21 dried extracts from seven plants were screened against protozoan parasites. 
Extracts were selected for further purification according to a slightly modified version of the 
protocol of Dua et al. 2011. The trypanocidal activities of the primary extracts were tested at a 
starting concentration of 400 µg/mL, as described by Dua et al. (2011). None of the methanol 
fractions showed measureable activity, probably because all the active ingredients had already 
11 
 
been extracted by the earlier hexane and ethyl acetate washes. Another notable observation was 
that none of the extracts showed reduced activity against the multi-drug resistant strain B48, and 
are therefore not cross-resistant with first-line trypanosomiasis drugs such as pentamidine, 
melarsoprol, diminazene and Cymelarsan. The one exception was the hexane extract of plant A, 
which was in fact significantly more active against B48 (P<0.001; Fig. 1). 
 The trypanocidal activities of the hexane (H) and ethyl acetate (E) extracts with EC50 
values <100 μM are depicted in Figure 1, and a full list is given in Table 3. Of particular interest 
were those with an EC50 value below 15 μg/mL, being the hexane extract of plant D (HDK-DH, 
2.4 ± 0.1 µg/mL), and the ethyl acetate extracts of plants E (HDK-EE. 4.2 ± 0.7 µg/mL) and F 
(HDK-FE, 12.3 ± 0.3 μg/mL); these were selected for further purification.  
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Figure 1. Drug sensitivity assays with medicinal plant extracts against T. brucei s427WT and 
B48 cell lines. The figure shows all the EC50 values from hexane (H), ethyl acetate (E) and 
methanol (M) extracts that could be obtained using the protocol described in the Methods 
section. When not shown the EC50 value was >400 µg/mL. The hexane fraction of Centrosema 
pubescens (HDK-AH) was more active against multi-drug resistant strain B48 than against 
wild type s427; no other significant differences (p<0.05) between the two strains were 
observed. Bars represent the average EC50 values and SEM of at least three independent 
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determinations. ***, P<0.001 by Student’s unpaired t-test. The dotted line identifies the 
fractions with EC50 values ≤15 μg/mL. 
 
3.2 In vitro selectivity of extracts: therapeutic index relative to Human Embryonic Kidney 
cells  
All 21 crude extracts from the seven medicinal plants were tested on Human Embryonic Kidney 
(HEK) 293-T cells in vitro, using a modified, and more sensitive, resazurin assay, involving a 
total incubation period of 78 hours. The result showed that at high doses extracts HDK-CH, 
HDK-DH, HDK-EE, and HDK-FH displayed a cytostatic, rather than cytotoxic, activity against 
HEK cells (EC50 <100 μM), whereas other extracts displayed less toxicity (Table 3). Indeed, no 
EC50 value could be obtained for 11 out of 21 extracts, using a top concentration of 400 µg/mL. 
The selectivity index (SI), defined as the in vitro EC50 value of the extract against the host cell 
divided by the EC50 value against the target cell, reached >20 but could not be determined where 
either EC50 value could not be obtained due to either low efficacy or low toxicity.  
Table 3. EC50 value, Resistance Factor (RF) and Selectivity Index (SI) of crude ethyl acetate 
(E), Hexane (H), and methanol (M) extracts from seven Nigerian medicinal plants. 
Fractions T.b. s427 WT 
(µg/mL) 
T.b. B48 
(µg/mL) 
RF HEK (293T) 
cells (µg/mL) 
SI 
HDK-AE 92.2 ± 2.1 ND ND >500 >5.4 
HDK-AH 74.3 ± 4.2 40.3 ± 2.1 0.543 386 ± 24 5.2 
HDK-AM 233 ± 11 ND ND >500 >2 
HDK-BE 71.5 ± 8.0 67.3 ± 2.4 0.94 492 ± 37 6.9 
HDK-BH 41.0 ± 1.9 42.6 ± 6.2 1.04 >500  >12 
HDK-BM >250 ND ND >500 ≥2 
HDK-CE 50.1 ± 5.2 60.8 ± 0.5 1.22 198 ± 12 4.0 
HDK-CH 22.0 ± 2.6 27.1 ± 0.8 1.23 80.0 ± 17 3.6 
HDK-CM 222 ± 5 ND ND >500  >2 
HDK-DE 15.2 ± 1.0 16.9 ± 0.2 1.11 114 ± 3  7.5 
HDK-DH 2.4 ± 0.1 6.8 ± 0.1 2.93 50.9 ± 2.2 21.6 
HDK-DM 129 ± 18 ND ND >500  >3.9 
HDK-EE 4.2 ± 0.7 5.4 ± 0.1 1.28 56.2 ± 1.9  13.3 
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HDK-EH 98.5 ± 1.1 ND ND >500 >5 
HDK-EM 150 ± 10 ND ND >500  >3.3 
HDK-FE 12.3 ± 0.3 12.0 ± 0.1 0.98 246 ± 17 20.1 
HDK-FH 18.4 ± 0.1 25.4 ± 0.5 1.383 86.9 ± 9.9 4.7 
HDK-FM 141 ± 16 ND ND >500 >2.8 
HDK-GE >500 ND ND 378 ± 17 <1 
HDK-GH >500 ND ND >500 ND 
HDK-GM >500 ND ND >500 ND 
Pentamidine 3.4 ± 0.51 1040 ± 1801 305 ND ND 
PAO2 ND ND ND 118 ± 61 ND 
Results were expressed as average EC50 of at least three independent determinations. Extracts 
HDK-CH, HDK-DH, HDK-EE, and HDK-FH were cytostatic rather than cytotoxic at high 
doses on HEK cells. Values are average of EC50 values of 4 independent determinations, 
expressed in µg/mL. 1EC50 values for pentamidine and PAO are given in nM. 2PAO, 
phenylarsine oxide. 3P<0.001, Student’s unpaired t-test t-test, comparing WT and B48. ND, not 
determined. 
 
3.3 Anti-Leishmanial activity of the primary plant extracts  
In order to determine the in vitro anti-leishmania activity of extracts from the selected plants, 
the extracts were tested on Leishmanial mexicana (M379) promastigotes (Fig. 2). The result 
revealed that hexane extracts from Tridax procumbens and Polyalthia longifolia (HDK-CH and 
HDK-DH) gave the best activity against L. mexicana in vitro (EC50 values of 16.8 and 17.2 
µg/mL respectively), while hexane extracts from Moringa oleifera (HDK-BH), Newbouldia 
laevis (HDK-EH), Eucalyptus maculata (HDK-FH), and ethyl acetate fractions of Tridax 
procumbens (HDK-CH) and Polyalthia longifolia (HDK-DH) all displayed moderate anti-
leishmanial activity in vitro (EC50 50-70 µg/mL). Extracts not included in figure 2 were inactive 
against L. mexicana under our experimental condition. There is only moderate correlation 
between the antileishmanial and antitrypanosomal activities of these extracts, but, importantly, 
extract HDK-DH displayed the strongest activity against both of the parasites.  
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Figure 2. Effect of Nigerian plant extracts on L. mexicana promastigotes. The data shown 
are the average EC50 ± SEM of three separate experiments. Inset:  pentamidine (PMD), a 
standard drug, was used as internal control. 
 
3.4 Bioactivity-guided isolation of the active constituents from extracts 
Between 150 - 200 fractions were collected from the column for each extract selected for 
fractionation, and the isolation of active compound was guided by the activity of each fraction. 
Progress of purification was monitored with NMR and mass spectrometric techniques. 
After column chromatography the HDK-DH crude extracts yielded a fraction that was 
very active against trypanosomes. This was followed by further purification on a Sephadex 
column, which gave a pure and active compound, analyzed by 1H and 13C-NMR. Nuclear 
Overhauser Experiments, HMBC, HQSC, and COSY were then carried out to determine the 
exact structure and relative stereoisomer. Mass spectrometry was also performed to confirm the 
structure and its purity. The result was a clerodane-type diterpenoid with an alpha,beta-
unsaturated lactone ring in the side chain identified as clerodane (16-α-hyroxy-cleroda-3-13(-
14)-Z-dien-15,16-olide; HDK-20). 
In addition, polyalthialdioc acid (HDK-79) and Kolavenic acid (HDK-52) were also 
isolated pure from other fractions of the crude hexane extract of plant D, Polyalthia longifolia  
(Figure 3). 
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HDK-20                     HDK- 79                           HDK-52                                       HDK-40 
Figure 3. Anti-kinetoplastid compounds isolated from Polyalthia longifolia (HDK - 20, 79 and 
52) and Eucalyptus maculata (HDK-40). HDK-20 is 16-α-hyroxy-cleroda-3-13(-14)z-dien-
15,16-olide; HDK-79 is kolavenic acid; HDK-52 is polyalthiadioc acid; and HDK-40 is 3β,13β-
dihydroxy-urs-11-en-28-oic acid. 
   
Fractionation of extract HDK-FE yielded a series of compounds, including triterpenes, 
aromatics (xanthones), cinnamate/chalcone types, aliphatics, and triterpenoids. Some of these 
were found in combination in the fractions, or with other impurities. However, the active 
fraction on trypanosomes was, after chemical analyses, identified as an ursane type triterpenoid 
(C30H48O4; HDK-40) with a molecular weight of 472.36 g/mol. Signals for seven skeletal 
methyl groups, of which two were doublets and five were singlets, were contained in the 1H-
NMR spectrum. The presence of 30 carbon atoms in its 13C-NMR, coupled with the signal from 
the 1H-NMR spectrum was suggestive of the fact that this compound was an ursane-type 
triterpenoid. Furthermore, analyses of the 1H-NMR spectrum of this compound revealed two 
olefinic protons and a secondary hydroxyl group whose splitting pattern and chemical shift were 
characteristic of a 3β-equatorial hydroxy in the nucleus of a typical ursane-type triterpenoid. 
In addition, two active compounds were identified from the crude extract of HDK-EE. 
The NMR and mass spectrometry analyses revealed them to be pheophytin A and B (HDK-28 
and HDK-23 respectively) with molecular formula C55H74O5N4 and C55H72N4O6 and molecular 
masses of 870 and 885.18 g/mol respectively. 
 
3.5 Trypanocidal activity of the purified active compounds 
The isolated natural compounds were tested on wild-type s427 trypanosomes as well as a panel 
of s427-derived cell lines adapted to high levels of resistance of current and experimental 
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classes of trypanocides. B48 is highly resistant to virtually all diamidines and melaminophenyl 
arsenicals; AQP2/3-KO lacks the AQP2/AQP3 genetic locus and is moderately resistant to 
pentamidine and melarsoprol; TbAT1-KO is somewhat resistant to pentamidine and highly 
resistant to diminazene; R0.8 is highly resistant to inhibitors of cAMP phosphodiesterases 
TbrPDEB1 and B2 (Gould et al., 2013), an important class of new therapeutic leads against 
trypanosomiasis (Shakur et al., 2011; Gould et al., 2011). The results are summarized in Table 
4.  
Compound HDK-20 displayed the highest activity against s427-WT trypanosomes, with 
an EC50 value of 0.38 ± 0.05 µg/mL, corresponding to approximately 1 µM. HDK-23, HDK-40 
and HDK-79 also displayed activity below 5 µg/mL, but the activity of HDK-52 was rather 
disappointing at 12.3 µg/mL. HDK20, HDK-79 and HDK-52 are closely related compounds 
from the same plant, Polyalthia longifolia, and most likely metabolites of each other. Clearly, 
the sidechain appears to have a large impact on the trypanocidal activity with the closed β-
lactone highly effective; this gives a potential starting point for derivatization towards even 
higher anti-parasitic activity. 
Testing of all purified compounds on our panel of drug resistant trypanosome lines 
identified only minor variations in sensitivity, which although statistically significant in some 
cases, were always well below even a 2-fold difference from EC50 value against the wild-type 
control (Table 4), in contrast to very high levels of resistance to the control drugs. As the 
resistance mechanisms for these drug classes are now well understood both in standard 
laboratory strains and in field isolates (Bridges et al., 2007; Delespaux and De Koning, 2007; 
Munday et al., 2015) we can conclude with confidence that the natural compounds reported here 
are not cross-resistant with key trypanocide classes such as the diamidines, melaminophenyl 
arsenicals and PDE inhibitors. Indeed, HDK-52 was significantly more active against all the 
resistant strains of T. brucei than the wild type.  
 
3.6 Cytotoxicity of the purified compounds 
The purified compounds were tested for their effects on human embryonic kidney (HEK) cells, 
using the same protocol as used for the crude extracts, so as to determine whether the 
antiprotozoal activity is the result of general toxicity or is more specifically antiprotozoal. The 
toxicity assays showed that the natural compounds that have an effect on T. brucei have almost 
no inhibitory activity on HEK cell growth and viability. Selectivity indices (SI, EC50 of HEK 
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cells / EC50 of parasites) for trypanosomes are not shown as none of the compounds tested were 
toxic to HEK cells at the highest concentration tested (200 µg/mL) (Fig. 4). However, this 
means that SI values range between >8 for HDK-28 and >526 for HDK-20. We conclude that 
the purification increased not only the activity of the plant extracts but also dramatically 
improved the selectivity of the product. 
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Fig. 4. Cytotoxicity assay of natural compounds on HEK 293-T cells, with 24 h cyto-adherence, 
30 h incubation with drugs, and 24 h with sodium resazurin (alamar blue).None of the isolated 
compounds displayed sigmoidal curves, showing that they were not toxic to mammalian cells at 
concentrations >200 mg/mL. The experiment shown was representative of three independent 
repeats with identical outcomes. 
 
3.7 Activity of Purified compounds against Trypanosoma congolense and Leishmania 
mexicana. 
The purified compounds were next tested against T. congolense in order to determine their 
prospects of being developed and used as veterinary drugs to treat animal African 
trypanosomiasis (AAT or nagana), a condition that causes billions of dollars in economic losses 
in sub-Sharan Africa (Giordani et al., 2016). Most of the compounds were somewhat less potent 
against T. congolense than against T. brucei under the assay conditions, but displayed a similar 
order of potency: HDK-20 >> HDK-40 > HDK-52 = HDK-79. In addition, the compounds were 
tested against L. mexicana promastigotes. As for the other two protozoan species, HDK-20 was 
the most potent of the compounds tested, and the order against L. mexicana was HDK-20 >> 
HDK-52 > HDK-40 > HDK-79. Figure 5 displays the EC50 values against all three pathogens 
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side-by-side. The level of anti-parasite activity for HDK-20 makes this a promising lead 
compound against kinetoplastid pathogens. 
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Figure 5. Effects of purified natural compounds against three pathogenic protozoa: 
bloodstream forms of T. brucei s427 and T. congolense strain IL3000, and promastigotes of L. 
mexicana strain M379. EC50 values shown are the average and SEM of 3 - 4 independent 
determinations.
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4. Discussion 
 
There is an increased interest in the antiprotozoal screening of plant extracts related to 
traditional therapy (Ndjakou Lenta et al., 2007; Osorio et al., 2007), apparently due to their very 
low toxicity, the stability of natural compounds, and their reported reduced prospects for 
resistance or cross resistance to existing drugs (Nour et al., 2009). We report here on the 
antiprotozoal activity of the extracts of seven Nigerian medicinal plants.  
 
Several of the crude ethyl acetate and hexane extracts displayed promising activity, whereas the 
methanol extracts were markedly less active. The low activity of the methanol extracts may 
simply be the result of the plants material already having been extracted with hexane and ethyl 
acetate, or genuinely indicate that the less polar solutes from these plants have the best anti-
protozoal activity. The polar compounds extracted by methanol generally display less cellular 
penetration than hydrophobic ones (Orsi and Essex, 2010), and this may contribute to the lack 
of in vitro anti-parasite activity.  
 
The extracts of C. pubescens, M. oleifera, T. procumbens and J. tanjorensis (plants A, B, C and 
G, respectively) did not display any significant in vitro anti-trypanosomal activity under our 
experimental design. However, these plants may contain compounds with other anti-protozoal 
or antibacterial activities, for which we did not test in the current study. Furthermore, the plants 
may in fact contain anti-trypanosomal compounds, but perhaps only in low amounts at the time 
of gathering the material. It must also be remembered that in the traditional usage the plant 
preparations are taken orally and the active principle may be activated in vivo.  
 
It has previously been reported that Nigerian medicinal plants contain active anti-parasite 
constituents (Ene et al., 2014; Igoli et al., 2011). However, the plants that we report on here 
have not previously been investigated for their anti-kinetoplastid activities, nor have their active 
compounds been identified before now. The only exception is a report that methanol extracts of 
P. longifolia leaves (our plant D) inhibit the growth of L. donovani promastigotes, with an IC50 
value of 4.18 µg/mL (Pal et al., 2011). In our screens, too, P. longifolia displayed the most 
promising anti-leishmanial activity, with the crude hexane extract displaying a similar IC50 
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against L. mexicana promastigotes. P. longifolia leaf extracts have also been reported to possess 
activity against pathogenic fungi such as Candida albicans, and against gram-positive bacteria, 
particularly Staphylococcus aureus, but not against gram-negative strains (Chanda and Nair, 
2010).  
The second-most promising medicinal plant in our study was E. maculata (plant F), with both 
the ethyl acetate and hexane extracts displaying anti-trypanosomal EC50 values below 20 
µg/mL; this  was apparently attributable the presence of the ursane type triterpene HDK-40, 
isolated from the ethyl acetate extract. Several previous studies reported anti-infectious 
activities of Eucalyptus species. Extracts of E. maculata leaves with methanol-dichloromethane 
were previously shown to have activity against gram-positive bacteria (Takahashi et al., 2004). 
Extracts from E. sideroxylon and E. torquata similarly displayed activity against gram-positive 
bacteria and some fungi (Ashour, 2008), and the ethyl acetate fraction from E. camaldulensis 
displayed a 100% growth inhibition against the protozoan Trichomonas vaginalis in vitro at a 
concentration of 12.5 mg/mL (Hassani et al., 2013).  
Extracts of N. laevis (plant E) have been reported to exercise anti-diabetic (ethanolic extract of 
leaves; Kolawole and Akanji, 2013), bactericidal (methanolic leaf extract; Usman and Osuji, 
2007), analgesic and anti-inflammatory (ethanolic flower extract; Usman et al., 2008) activities 
but we are not aware of any studies regarding their anti-protozoan activities. Here, we report the 
anti-kinetoplastid activity of N. laevis and attribute its activities to the presence of pheophytin, a 
compound that was previously isolated from Loniera hypoglauca in a screen for activity against 
hepatitis C virus, and was shown to inhibit its NC3 serine protease (Wang et al., 2009). We 
found both pheophytin A and B to exhibit a good level of anti-trypanosomal activity, but 
pheophytin B was approximately 15-fold more potent than pheophytin A.  
 
Our initial NMR data revealed the presence of some common classes of active compounds in 
these plants under study, including terpeniods, aromatics, and pheophytins  (Salem and 
Werbovetz, 2006; Wink, 2012). We attribute the remarkable anti-kinetoplastid activity of 
Polyalthia longifolia extracts and their isolated compounds observed in this study to the 
presence of clerodane diterpenes, of which the closed lactone form, HDK-20, was more active 
against the kinetoplastids than the aldehyde or carboxylic acid moieties on the scaffold. HDK-
20 and HDK-79 have previously been described in extracts of P. longifolia, with antifeedant 
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(Phadnis et al., 1988) and anti-inflammatory properties (inhibition of NO production by 
macrophages; Wu et al., 2014). 
 
Wink (2008) reported that lipophilic secondary metabolites like the terpenoids have detergent-
like properties that can disrupt biological membranes, alter their fluidity and inhibit the function 
of membrane proteins, including those involved in cellular signaling and transport. Although we 
observed no major differences in activity against our cell lines with altered drug transport (B48, 
AQP2/3-KO, AT1-KO) or cAMP signaling (R0.8), HDK-52 consistently displayed a 
significantly higher activity against the transporter mutants than against the wild-type, a 
situation that was reversed for HDK-79, and both were somewhat less effective against the 
cAMP-desensitized clone R0.8 as well. However, we do not propose that chemical disruption of 
the lipid bilayer can be the main mode of action of these compounds, as this would fail to 
explain the considerable selectivity vis-à-vis the Leishmania mexicana or human cells. 
 
The active principles isolated in this work could be potentially developed to treat either human 
or animal African trypanosomiasis (HAT and AAT, respectively). Whereas HAT, commonly 
known as sleeping sickness, is a devastating, fatal disease, its disease burden is steadily 
declining (Simarro et al., 2015) while AAT continues to cause huge economic losses, and places 
serious limitations on agriculture in sub-Saharan Africa – not just for cattle rearing (beef, dairy) 
but also for draught power for ploughs, carts, etc. The main AAT pathogens are Trypanosoma 
congolense and Trypanosoma vivax (Giordani et al., 2016), and we therefore also tested some of 
the active principles on in vitro cultures of T. congolense. Interestingly, the same order of 
potency for these compounds applied for both T. brucei and T. congolense, with HDK-20 again 
being by far the most active agent. Together with the similarly potent activities against multi-
drug resistant trypanosome lines, this appears to indicate that the clerodane diterpenes may have 
general utility against African trypanosomes. This is important, as African livestock may be 
infected by any of several Trypanosoma species and any drug must be able to act on all of them, 
as identification of (sub)-species for individual animals is currently impracticable. Although the 
bio-assay fractionation was guided by activity against T. brucei, the extracts and their isolated 
compounds were also tested on L. mexicana, as the plants are considered to have broad activity 
against protozoan infections. The anti-Leishmania efficacy of some of these plants (hexane 
extracts of T. procumbans and P. longifolia) and their purified compounds (HDK-20), affirms 
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their continuous use in folkloric medicine, and we propose that at least some of the plants are 
good prospects for new drugs against kinetoplastid diseases. 
 
5. Conclusion 
Our results have shown that the medicinal plants used in this research are reservoirs of active 
principles against trypanosomes; these natural compounds are nontoxic to mammalian cells in 
vitro and with no prospects for cross-resistance with existing drugs like pentamidine, 
melarsoprol, cymelarsan and diminazene aceturate. The active principles identified could serve 
as lead compounds towards the identification of more efficient anti-trypanosome drugs. We 
conclude that the Nigerian flora is indeed an appropriate starting point in the search for new and 
more efficient anti-kinetoplastid molecules, and that our results validate the traditional usage of 
at least some of these plants for the treatment of tropical fevers.  
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